Achilles Therapeutics is betting that its clonal neoantigen-targeting T cell (cNeT) products, combined with an industrial scale advanced manufacturing capability and predictive bioinformatics platform, will have a transformational impact on patients with solid tumors and metastasized cancer.
Syncona biotech firm Achilles Therapeutics Ltd. was founded in 2016 as a spin off from the Francis Crick Institute and University College London. It was built on the work of thoracic oncologist Charles Swanton, a founder of Achilles Therapeutics and chief clinician at Cancer Research UK (CRUK).
Swanton also leads the CRUK-sponsored TRACERx (TRAcking Cancer Evolution through therapy (Rx)) lung study, a nine-year, multi-million-dollar research project aimed...
BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.
Exec summary XXXXXXX
Patrick Alexandre, Crossject CEO, discusses crucial developments happening for Zeneo, a needle-free injector, functioning intramuscularly to administer medication in a tenth of a second
The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.
